VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Bre
VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Breast Oncology Program at the University of Michigan Cancer Center Ann Arbor. After his talk on the utility of genetic signatures to select adjuvant treatment he discussed his findings and conclusions with Oncology Time reporter Sarah Maxwell.